Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 29, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing...
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023 08:00 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to...
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05, 2023 12:54 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing...
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
November 29, 2023 10:20 ET
|
Altamira Therapeutics Ltd
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29,...
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 17, 2023 09:04 ET
|
Altamira Therapeutics Ltd
Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue ...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 10, 2023 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing...
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 14, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in...
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023 07:30 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company...
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
September 06, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...